CP-481,715 Nickel Allergy Study.

Completed · Phase 1

Conditions studied: Dermatitis, Allergic Contact

In brief

To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.

Key facts

Study ID

NCT00141180

Run by

Pfizer

People needed

48

Starts

2003-09-01

Expected to finish

2005-10-01

Last updated by the study team

2006-07-25

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• A history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to T.R.U.E. TEST.

You may not qualify if…

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding contact allergic dermatitis or untreated, asymptomatic, seasonal allergies at time of dosing).

Where it is running

• Pfizer Investigational Site — Ann Arbor, Michigan, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Austin, Texas, United States
• Pfizer Investigational Site — Bryan, Texas, United States
• Pfizer Investigational Site — Hellerup, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.